Robert C. Scott

14.9k total citations · 15 hit papers
146 papers, 11.1k citations indexed

About

Robert C. Scott is a scholar working on Surgery, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Robert C. Scott has authored 146 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Surgery, 36 papers in Economics and Econometrics and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Robert C. Scott's work include Lipoproteins and Cardiovascular Health (56 papers), Pharmaceutical Economics and Policy (16 papers) and Health Systems, Economic Evaluations, Quality of Life (12 papers). Robert C. Scott is often cited by papers focused on Lipoproteins and Cardiovascular Health (56 papers), Pharmaceutical Economics and Policy (16 papers) and Health Systems, Economic Evaluations, Quality of Life (12 papers). Robert C. Scott collaborates with scholars based in United States, United Kingdom and Australia. Robert C. Scott's co-authors include Scott M. Wasserman, Evan A. Stein, Frederick J. Raal, Sarah Gould, Philip A. Horvath, Michael J. Koren, Dirk Blom, Ransi Somaratne, Robert P. Giugliano and Marc S. Sabatine and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Robert C. Scott

140 papers receiving 10.7k citations

Hit Papers

Efficacy and Safety... 1980 2026 1995 2010 2015 2016 2005 2014 2014 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
    2015 1.1k citations Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine profile →
  2. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
    2016 791 citations Stephen J. Nicholls, Rishi Puri et al. profile →
  3. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review
    2005 615 citations Robert C. Scott et al. Food and Chemical Toxicology profile →
  4. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
    2014 562 citations Frederick J. Raal, Evan A. Stein et al. The Lancet profile →
  5. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
    2014 553 citations Dirk Blom, Michael J. Koren et al. New England Journal of Medicine profile →
  6. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
    2014 553 citations Frederick J. Raal, Narimon Honarpour et al. The Lancet profile →
  7. On The Direction of Preference for Moments of Higher Order Than The Variance
    1980 501 citations Robert C. Scott et al. profile →
  8. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
    2014 421 citations Gerald F. Watts, Leslie Cho et al. profile →
  9. Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
    2014 407 citations Jennifer G. Robinson, Ransi Somaratne et al. profile →
  10. Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
    2012 403 citations Frederick J. Raal, Robert C. Scott et al. profile →
  11. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
    2012 369 citations Robert C. Scott, Scott M. Wasserman et al. profile →
  12. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
    2012 354 citations Robert P. Giugliano, Nihar R. Desai et al. The Lancet profile →
  13. Anti-PCSK9 Monotherapy for Hypercholesterolemia
    2014 338 citations Michael J. Koren, Jingyuan Yang et al. profile →
  14. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
    2012 297 citations Michael J. Koren, Robert C. Scott et al. The Lancet profile →
  15. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
    2014 281 citations Frederick J. Raal, Robert P. Giugliano et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert C. Scott United States 42 7.8k 3.3k 1.7k 1.5k 1.4k 146 11.1k
Wai K. Leung Hong Kong 67 7.4k 0.9× 373 0.1× 259 0.2× 1.3k 0.9× 917 0.7× 387 16.5k
Thomas J. Cook United States 35 2.0k 0.3× 727 0.2× 1.1k 0.7× 747 0.5× 162 0.1× 107 5.3k
Philip Hougaard Denmark 45 1.7k 0.2× 712 0.2× 2.8k 1.6× 774 0.5× 180 0.1× 104 8.5k
Ram C. Tiwari United States 27 1.8k 0.2× 599 0.2× 356 0.2× 204 0.1× 518 0.4× 223 11.9k
Robert M. Elashoff United States 73 2.6k 0.3× 373 0.1× 1.4k 0.8× 1.1k 0.8× 2.2k 1.6× 267 21.0k
Grace Lai–Hung Wong Hong Kong 90 4.1k 0.5× 380 0.1× 4.3k 2.5× 1.4k 1.0× 428 0.3× 556 27.2k
Rongshou Zheng China 55 5.2k 0.7× 571 0.2× 688 0.4× 239 0.2× 1.8k 1.2× 204 28.8k
Siwei Zhang China 56 5.1k 0.6× 504 0.2× 709 0.4× 244 0.2× 1.9k 1.3× 235 28.3k
Daniel F. Heitjan United States 61 1.3k 0.2× 735 0.2× 350 0.2× 679 0.5× 834 0.6× 229 12.7k
William R. Bell United States 52 2.0k 0.3× 898 0.3× 309 0.2× 2.0k 1.4× 1.4k 1.0× 282 11.9k

Countries citing papers authored by Robert C. Scott

Since Specialization
Citations

This map shows the geographic impact of Robert C. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Scott more than expected).

Fields of papers citing papers by Robert C. Scott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert C. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Scott. The network helps show where Robert C. Scott may publish in the future.

Co-authorship network of co-authors of Robert C. Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Robert C. Scott. A scholar is included among the top collaborators of Robert C. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert C. Scott. Robert C. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chan, Dick C., Gerald F. Watts, Ransi Somaratne, et al.. (2018). Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arteriosclerosis Thrombosis and Vascular Biology. 38(7). 1644–1655. 28 indexed citations
2.
Watts, Gerald F., Dick C. Chan, Ransi Somaratne, et al.. (2018). Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. European Heart Journal. 39(27). 2577–2585. 113 indexed citations
3.
Desai, Nihar R., Robert P. Giugliano, Scott M. Wasserman, et al.. (2017). Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. JAMA Cardiology. 2(5). 556–556. 23 indexed citations
4.
Povsic, Thomas J., Robert C. Scott, Kenneth W. Mahaffey, et al.. (2017). Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovascular Drugs and Therapy. 31(4). 445–458. 8 indexed citations
5.
6.
Sabatine, Marc S., Robert P. Giugliano, Stephen D. Wiviott, et al.. (2015). Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine. 372(16). 1500–1509. 1091 indexed citations breakdown →
7.
Sabatine, Marc S., Robert P. Giugliano, Anthony Keech, et al.. (2015). Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal. 173. 94–101. 130 indexed citations
8.
Scott, Robert C., et al.. (2015). The Joined Wing. NASA Technical Reports Server (NASA). 1 indexed citations
9.
Raal, Frederick J., Narimon Honarpour, Dirk Blom, et al.. (2014). Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet. 385(9965). 341–350. 553 indexed citations breakdown →
10.
Khairat, Saif, et al.. (2014). Building a Multicenter Telehealth Network to Advance Chronic Disease Management. Studies in health technology and informatics. 202. 299–302. 6 indexed citations
11.
Gretz, Richard T., et al.. (2011). R&D Subsidy Games: A Cost Sharing Approach vs. Reward for Performance. SSRN Electronic Journal. 1 indexed citations
12.
Gretz, Richard T., Joshua J. Lewer, & Robert C. Scott. (2010). R&D, Risk, and the Role of Targeted Government R&D Programs. SSRN Electronic Journal. 36(1). 79–104. 1 indexed citations
13.
Wang, Bin, et al.. (2008). Modeling Oxygenation and Selective Delivery of Drug Carriers Post-Myocardial Infarction. Advances in experimental medicine and biology. 614. 333–343. 5 indexed citations
14.
Silva, Walter A., et al.. (2003). Identification of Computational and Experimental Reduced-Order Models. 8 indexed citations
15.
Scott, Robert C., et al.. (1993). Methods for measuring dermal penetration of pesticides. Food and Chemical Toxicology. 31(7). 523–529. 7 indexed citations
16.
Scott, Robert C., et al.. (1990). The Influence of Skin Structure on Permeability: An Intersite and Interspecies Comparison with Hydrophilic Penetrants. Journal of Investigative Dermatology. 96(6). 921–925. 62 indexed citations
17.
Viano, David C., et al.. (1989). Involvement of older drivers in multi-vehicle side impact crashes. 33. 337–352. 5 indexed citations
18.
Scott, Robert C. & R. H. Marrs. (1984). Impact of Japanese knotweed and methods of control. Aspects of applied biology. 91–296. 8 indexed citations
19.
Scott, Robert C., et al.. (1983). Catastrophe Theory in Economics. The Journal of Economic Education. 14(3). 48–59. 1 indexed citations
20.
Scott, Robert C. & Martin T. Farris. (1974). AIRLINE SUBSIDIES IN THE UNITED STATES. Transportation Journal. 13(4). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wai K. Leung Breakdown of academic impact, for papers by Thomas J. Cook Breakdown of academic impact, for papers by Philip Hougaard Breakdown of academic impact, for papers by Ram C. Tiwari Breakdown of academic impact, for papers by Robert M. Elashoff Breakdown of academic impact, for papers by Grace Lai–Hung Wong Breakdown of academic impact, for papers by Rongshou Zheng Breakdown of academic impact, for papers by Siwei Zhang Breakdown of academic impact, for papers by Daniel F. Heitjan Breakdown of academic impact, for papers by William R. Bell
Rankless by CCL
2026